Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response

Abstract excerpt

KRAS (Kirsten rat sarcoma viral oncogene homolog) is a major target in pancreatic ductal adenocarcinoma (PDAC), but so far it has been perceived as “undruggable”, due to a lack of effective inhibitors. Kinsey et al . (1) have recently reported that inhibition of the RAF (rapidly accelerated fibrosarcoma)→MEK (MAPK/ERK kinase)→MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy in Disease and Therapy
• Share to Cancer Mechanisms and Therapy
• Share to Pancreatic and Hepatic Oncology Research